

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

## **Concomitant Treatment of Malignant Brain Tumours With CBD – A Case Series and Review of the Literature**

RUDOLF LIKAR<sup>1</sup>, MARKUS KOESTENBERGER<sup>1</sup>, MARTIN STULTSCHNIG<sup>2</sup> and GERHARD NAHLER<sup>3</sup>

*<sup>1</sup>Department of Anaesthesiology and Intensive Care,*

*Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria;*

*<sup>2</sup>Neurological Department, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria;*

*<sup>3</sup>CIS Clinical Investigation Support GmbH, Vienna, Austria*

*Reprinted from*

ANTICANCER RESEARCH 39: 5797-5801 (2019)

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005  
ISSN (online): 1791-7530

## Editorial Board

P. A. ABRAHAMSSON, Malmö, Sweden  
B. B. AGGARWAL, Houston, TX, USA  
T. AKIMOTO, Kashiwa, Chiba, Japan  
P. Z. ANASTASIADIS, Jacksonville, FL, USA  
A. ARGIRIS, San Antonio, TX, USA  
J. P. ARMAND, Toulouse, France  
V. I. AVRAMIS, Los Angeles, CA, USA  
D.-T. BAU, Taichung, Taiwan, ROC  
G. BAUER, Freiburg, Germany  
E. E. BAULIEU, Le Kremlin-Bicetre, France  
E. J. BENZ, Jr., Boston, MA, USA  
J. BERGH, Stockholm, Sweden  
F. T. BOSMAN, Lausanne, Switzerland  
M. BOUVET, La Jolla, CA, USA  
J. BOYD, Miami, FL, USA  
G. BROICH, Monza, Italy  
Ø. S. BRULAND, Oslo, Norway  
J. M. BUATTI, Iowa City, IA, USA  
M. M. BURGER, Basel, Switzerland  
M. CARBONE, Honolulu, HI, USA  
C. CARLBERG, Kuopio, Finland  
J. CARLSSON, Uppsala, Sweden  
A. F. CHAMBERS, London, ON, Canada  
P. CHANDRA, Frankfurt am Main, Germany  
L. CHENG, Indianapolis, IN, USA  
J.-G. CHUNG, Taichung, Taiwan, ROC  
R. CLARKE, Washington, DC, USA  
E. DE CLERCQ, Leuven, Belgium  
W. DEN OTTER, Amsterdam, The Netherlands  
E. P. DIAMANDIS, Toronto, ON, Canada  
G. TH. DIAMANDOPOULOS, Boston, MA, USA  
L. EGEVAD, Stockholm, Sweden  
D. W. FELSHER, Stanford, CA, USA  
J. A. FERNANDEZ-POL, Chesterfield, MO, USA  
I. J. FIDLER, Houston, TX, USA  
A. P. FIELDS, Jacksonville, FL, USA  
H. FU, Atlanta, GA, USA  
B. FUCHS, Zurich, Switzerland  
D. FUCHS, Innsbruck, Austria  
D. FUKUMURA, Boston, MA, USA  
G. GABBIANI, Geneva, Switzerland  
R. GANAPATHI, Charlotte, NC, USA  
A. F. GAZDAR, Dallas, TX, USA  
A. GIORDANO, Philadelphia, PA, USA  
G. GITSCH, Freiburg, Germany  
M. GNANT, Vienna, Austria  
R. H. GOLDFARB, Guilford, CT, USA  
A. HELLAND, Oslo, Norway  
L. HELSON, Quakertown, PA, USA  
R. HENRIKSSON, Umeå, Sweden  
R. M. HOFFMAN, San Diego, CA, USA  
S. C. JHANWAR, New York, NY, USA  
J. V. JOHANNESSEN, Oslo, Norway  
R. JONES, London, UK  
B. KAINA, Mainz, Germany  
P. -L. KELLOKUMPU-LEHTINEN, Tampere, Finland  
D. G. KIEBACK, Schleswig, Germany  
R. KLAPDOR, Hamburg, Germany  
H. KOBAYASHI, Bethesda, MD, USA

S. D. KOTTARIDIS, Athens, Greece  
G. R. F. KRUEGER, Köln, Germany  
Pat M. KUMAR, Manchester, UK  
Shant KUMAR, Manchester, UK  
O. D. LAERUM, Bergen, Norway  
F. J. LEJEUNE, Lausanne, Switzerland  
S. LINDER, Linköping, Sweden  
L. F. LIU, Piscataway, NJ, USA  
D. M. LOPEZ, Miami, FL, USA  
E. LUNDGREN, Umeå, Sweden  
Y. MAEHARA, Fukuoka, Japan  
J. MAHER, London, UK  
J. MARESCAUX, Strasbourg, France  
J. MARK, Skövde, Sweden  
S. S. MARTIN, Baltimore, MD, USA  
S. MITRA, Houston, TX, USA  
S. MIYAMOTO, Fukuoka, Japan  
S. MONCADA, Manchester, UK  
M. MUELLER, Villingen-Schwenningen, Germany  
F. M. MUGGIA, New York, NY, USA  
M. NAMIKI, Kanazawa, Ishikawa, Japan  
R. NARAYANAN, Boca Raton, FL, USA  
K. NILSSON, Uppsala, Sweden  
S. PATHAK, Houston, TX, USA  
J.L. PERSSON, Malmö, Sweden  
G. J. PILKINGTON, Portsmouth, UK  
C. D. PLATSOUKAS, Norfolk, VA, USA  
A. POLLIACK, Jerusalem, Israel  
D. RADES, Lübeck, Germany  
M. RIGAUD, Limoges, France  
U. RINGBORG, Stockholm, Sweden  
M. ROSELLI, Rome, Italy  
S.T. ROSEN, Duarte, CA, USA  
A. SCHAUER, Göttingen, Germany  
M. SCHNEIDER, Wuppertal, Germany  
J. SEHOULI, Berlin, Germany  
A. SETH, Toronto, ON, Canada  
G. V. SHERBET, Newcastle-upon-Tyne, UK  
A. SLOMINSKI, Birmingham, AL, USA  
G.-I. SOMA, Kagawa, Japan  
G. S. STEIN, Burlington, VT, USA  
T. STIGBRAND, Umeå, Sweden  
T. M. THEOPHANIDES, Athens, Greece  
P. M. UELAND, Bergen, Norway  
H. VAN VLIERBERGHE, Ghent, Belgium  
R. G. VILE, Rochester, MN, USA  
M. WELLER, Zurich, Switzerland  
J. WESTERMARCK, Turku, Finland  
B. WESTERMARK, Uppsala, Sweden  
Y. YEN, Taipei, Taiwan, ROC  
M.R.I. YOUNG, Charleston, SC, USA  
B. ZUMOFF, New York, NY, USA  
G. J. DELINASIOS, Athens, Greece  
Managing Editor and  
Executive Publisher  
J. G. DELINASIOS, Athens, Greece  
Managing Editor (1981-2016)

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

**U.S. Branch:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iia-anticancer.org  
Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IAR is a member of UICC. For more information about ANTICANCER RESEARCH, IAR and the Conferences, please visit the IAR website: www.iia-anticancer.org

**Publication Data:** ANTICANCER RESEARCH (AR) is published bimonthly from January 1981 to December 2008 and monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

**Copyright:** On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

**Annual Subscription Rates 2019 per volume:** Institutional subscription US\$ 1,898.00 (online) or US\$ 2,277.00 (print & online). Personal subscription US\$ 897.00 (online) or US\$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-38, 1981-2018) are available at 50% discount on the above rates.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: subscriptions@iia-anticancer.org)

**Advertising:** All correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIC) Data Bases.

Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit www.copyright.com and enter the title that you are requesting permission for in the 'Get Permission' search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750-8400. Fax: +1-978-646-8600. E-mail: info@copyright.com.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

D.T.P. BY IAR

PRINTED BY ENTYP0, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER

# Concomitant Treatment of Malignant Brain Tumours With CBD – A Case Series and Review of the Literature

RUDOLF LIKAR<sup>1</sup>, MARKUS KOESTENBERGER<sup>1</sup>, MARTIN STULTSCHNIG<sup>2</sup> and GERHARD NAHLER<sup>3</sup>

<sup>1</sup>*Department of Anaesthesiology and Intensive Care,*

*Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria;*

<sup>2</sup>*Neurological Department, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria;*

<sup>3</sup>*CIS Clinical Investigation Support GmbH, Vienna, Austria*

**Abstract.** *Grade IV glioblastoma multiforme is a deadly disease, with a median survival of around 14 to 16 months. Maximal resection followed by adjuvant radiochemotherapy has been the mainstay of treatment since many years, although survival is only extended by a few months. In recent years, an increasing number of data from in vitro and in vivo research with cannabinoids, particularly with the non-intoxicating cannabidiol (CBD), point to their potential role as tumour-inhibiting agents. Herein, a total of nine consecutive patients with brain tumours are described as case series; all patients received CBD in a daily dose of 400 mg concomitantly to the standard therapeutic procedure of maximal resection followed by radiochemotherapy. By the time of the submission of this article, all but one patient are still alive with a mean survival time of 22.3 months (range=7-47 months). This is longer than what would have been expected.*

Although relatively rare in absolute terms with an incidence of 3% of total cancer cases, brain tumours, in particular glioblastoma multiforme (GBM), rank among the deadliest diagnoses. GBM accounts for 12-15% of all intracranial tumours and 50 to 60% of astrocytic tumours. GBMs may manifest at any age, but mostly affect adults with a peak incidence between 45 and 75 years of age.

Brain tumours are on the rise. A recent random-effects model that analysed data from 1985 onwards found the overall incidence rate on all primary brain tumours to be 10.82 (95%CI=8.63-13.56) per 100,000 person-years (1).

*Correspondence to:* Dr. Gerhard Nahler, CIS Clinical Investigation Support GmbH, Kaiserstrasse 43, 1070 Vienna, Austria. Tel: +43 152340150, Fax: +43 1523401599, e-mail: nahler@aon.at

*Key Words:* Cannabidiol, cannabinoids, chemoradiation, brain tumours, glioblastoma multiforme.

According to a prognostic estimation by the Austrian Ministry of Health, the incidence of brain tumours will increase by 84% for men and 26% for women between 2010 and 2030; death rates will nearly double (2). Similar results come from the UK where brain tumour incidence rates increased by 36% since the early 1990s (3).

Depending on the location and possibility for surgical removal, each type of tumour has its own biology and risks. Survival rates for malignant brain tumours vary widely, depending on the type of tumour, its grade and the location in the brain, with glioblastoma multiforme grade IV having the worst prognosis with a median survival of around 14 to 16 months (4). Only about 8 to 12% of patients survive two years.

Among the most important prognostic factors are age (with younger patients having a better prognosis), molecular factors (*IDH1*, *IDH2*, *MGMT*, and a 1p/19q co-deletion), and tumour location/extent of surgical resection (possibility for complete resection). A major focus of epigenetic research is DNA-methylation, which involves addition or removal of methyl groups on cytosines in cytosine-phosphate-guanine (CpG) dinucleotides and is involved in the regulation of gene expression. Although morphologically identical, different GBM tumours may translate into different clinical outcomes.

The primary aim of interventions is to increase survival and to maintain an acceptable quality of life. The standard treatment of GBM is maximal safe resection followed by adjuvant radiotherapy with concurrent chemotherapy. Temozolomide (TMZ) in combination with radiation therapy has been shown to increase the median survival of patients with newly diagnosed GBM by 2 to 3 months, from 12.1 (radiotherapy alone) to 14.6 months (5, 6). Following TMZ treatment after GBM recurrence, only 21% of patients obtain a progression-free survival (PFS) of six months and a six-month overall survival (OS) of 60% (7).

A number of preclinical studies suggest that phytocannabinoids might be effective in glioma therapy (8). Although

cannabis including extracts containing phytocannabinoids have been reported to reduce the growth of brain tumours in adults (9, 10) as well as in children (11, 12), a major lacuna in the use of herbal cannabis and “CBD-oils” is their poor standardisation, the lack of information on the exact composition, lack of comparability, lack of reproducibility and poor quality control (13). Nabiximols, a standardised, ~1:1 combination of two pharmaceutical grade extracts, one enriched with delta-9-tetrahydrocannabinol (THC), and the other with CBD, was shown recently to increase median survival of patients with recurrent glioblastoma multiforme by about 6 months, from 369 days (placebo group) to over 550 days when added to a dose-intensive temozolomide therapy (14).

In contrast, pure THC as well as CBD, are available as defined active pharmaceutical ingredients. Nonetheless, and despite of the promising preclinical data, reports on treatment of brain tumours with pure cannabinoids are very rare. In a pioneering study, THC was instilled into the resection cavity of patients with recurrent glioblastoma multiforme that had failed previous standard therapy (15). In this study, which did not aim to prolong survival, 5 of 9 patients received more than 1 cycle, and in 3 of these 5 patients, a temporary reduction in tumour proliferation was observed. However, the psychotomimetic properties of THC and down-regulation of CB1 receptors limit dosage and treatment duration. The recent report on the beneficial effects of non-psychotropic CBD in cancer patients is the most actual and the only demonstration of a possible anti-tumour effect of pure CBD in man (16).

Crystalline CBD, isolated from hemp or as a synthetic substance, is available with a purity of at least 98% (Deutscher Arzneimittel Codex DAC/NRF 2016/2, C-052, Avoxa-Mediengruppe Deutscher Apotheker GmbH, Eschborn, Germany) for magisterial prescription in some European countries such as Austria, Germany, Switzerland and the UK. A few companies provide CBD with a purity of 99.8% or higher. CBD is therefore a well-defined alternative to extracts or dronabinol (THC) for anti-tumour therapy. Furthermore, CBD has been reported to be well-tolerated and to reduce epileptic seizures (for which CBD received marketing authorisation by the FDA in June 2018), pain, nausea and to improve quality of life.

Herein, we report experiences with magisterial preparations containing pure (>99.8%) phyto-CBD (source: Trigal Pharma GmbH, Wien, Austria) prepared by a local pharmacy as adjuvant treatment of brain cancer patients. All patients consented to receive magisterial CBD capsules, and the local ethics committee has approved the treatment with CBD.

## Case Presentations

Case 1, DI, female patient diagnosed at 38 years of age. In January 2018, an astrocytoma grade II located in the right

post-central area was removed. Her medical history showed that her father as well as her grand mother died of a grade IV glioblastoma. Post-surgery, she specifically asked for no other treatment than CBD which was started 6 months after craniotomy, beginning on July 2018 (2×100 mg CBD/day for the first 2 weeks, then 2×200 mg/day). With CBD, her pain (numerical rating scale/NRS) was reduced from 4 to 0-1 within 2 months. Disease is stable at present.

Case 2, EJ, male patient, firstly diagnosed at 13 years of age. In June 1991 an oligoastrocytoma grade III, left occipital, was removed, followed by radio-chemotherapy until November 1992. In May 2015 a new, intraventricular tumour, an atypical grade II meningioma, was diagnosed and removed. The intervention was followed by a transient reduction in his vision on both sites. Because of a possible re-formation of tumour masses, CBD (2×200 mg/day) was started in August 2018. The patient is well, without new problems noted until now.

Case 3, GJ, male patient. In October 2015, at the age of 40 years, a left temporal glioblastoma multiforme grade IV, was diagnosed following epileptic seizures and removed. Thereafter, treatment with bevacizumab, lomustine (CCNU) and radiotherapy (Tumour Treating Fields) was started. Epilepsy is treated with levetiracetam. CBD (2×200 mg/day) was started in the end of May 2017. Since then, no further epileptic seizures have occurred. According to the latest magnetic resonance imaging (MRI) the tumorous formation is marginally decreasing.

Case 4, HB, female patient diagnosed at 44 years of age. In March 2016 an incomplete resection of a right temporo-basal grade II oligodendroglioma was performed. CBD was started in February 2017 and increased stepwise up to 2×300 mg one month later. The patient received levetiracetam as an antiepileptic therapy and intermittently also dronabinol, but no radio- or other therapy were received except analgesics on demand. The MRI in April 2019 showed stable disease.

Case 5, HW, male patient diagnosed at 60 years of age. Following an epileptic seizure, computed tomography and MRI revealed a tumour mass located at the right side of the temporo-occipital lobe. A craniotomy in February 2019 demonstrated the presence of a grade IV glioblastoma multiforme with 50% necrotic tissue (ATRX preserved, IDH1 not mutated, p53 strongly positive, MIB-1 (Ki-67), highly proliferating and positive for GFAP, EGFR). Five weeks later, the patient was re-operated in order to remove residual, progressive tumour tissue. In the end of February, two weeks before the 2nd craniotomy, CBD was started (2×100 mg/day). From April 2019 onwards, the patient also received radio-chemotherapy with temozolomide. At present, there is no sign of tumour recurrence. The patient also receives lacosamid/vimpat to prevent epileptic seizures.

Case 6, KE, male patient, age at diagnosis 61 years. He presented with epileptic seizures in 2016. MRI showed a left

mesial-temporal lesion. Craniotomy was performed under ALA-control and a grade IV glioblastoma (MGMT hypermethylated, 1p19q-deletion) was partially removed in November 2016. Radio-chemotherapy was applied including temozolomide. Beginning in May 2017, comedication with CBD (2×200 mg/day) was started together with dronabinol (7.5 mg/day). The latest MRI in February 2019 demonstrated stable disease.

Case 7, OB, male patient; at the age of five years the child had epileptic seizures. Further examinations revealed an fronto-basal astrocytoma grade II, which was partially removed, followed by radiotherapy. Follow-up examinations in 1993 showed no progression of the lesion. At the age of 41 years, in the end of 2017, the patient complained of reduced sensibility and slight paresis in the left arm and leg. In February 2018, a new mass (measuring 5×5×4 cm) in the right fronto-parietal lobe, straddling close to the pyramidal tract, was detected by MRI and partially removed two days later. Histology demonstrated a grade IV glioblastoma multiforme. Further molecular-pathologic examinations revealed a methylated MGMT gene promoter. At this time the old remaining fronto-basal tumour did not show any progression. Postoperatively, the patient received radiotherapy and temozolomide. A control MRI one month after craniotomy in March 2018 showed progression of the fronto-basal tumour, and CBD (2×200 mg/day) was started as comedication. An MRI in July 2018 demonstrated a possible progression of the old, fronto-basal lesion which had not been irradiated after the intervention in February 2018, as well as changes on the recently operated lesion located in the right fronto-parietal lobe. Therefore, the patient was operated on again in August 2018. Following resection, this mass was diagnosed as necrotic/fibrotic. All MRI scans thereafter, in November 2018, February 2019 and June 2019 demonstrated stable conditions.

Case 8, TG, female patient diagnosed at 49 years of age. In October 2018, a grade IV glioblastoma multiforme (IDH1 negative, no loss of ATRX, expression of EGFR 10%), located at the right parieto-occipital lobe was partially removed, and radio-chemotherapy with temozolomide was started. In November 2018 CBD (2×200 mg/day) was added to the therapy. In February 2019 the patient was re-operated in order to remove the remained, mainly necrotic tumour tissue. At present, there is no sign of progression of the tumour.

Case 9, WC, female patient diagnosed at 35 years of age. In December 2017, a right fronto-parietal grade IV glioblastoma multiforme was partially removed. Radio-chemotherapy with temozolomide was started thereafter. As the tumour was progressive, CBD (2x 100 mg/day) was added to the treatment in March 2018. Over a period of 10 months a slight regression was observed. However, 11 months after diagnosis, the tumour resumed growth and the patient died two months later.

## Discussion

Since 2016, nine consecutive patients with brain tumours have received pure CBD in addition to standard treatment (maximal surgical removal of cancer tissue and radio-chemotherapy). Treatment with CBD started with 100 mg twice daily and was increased usually to 200 mg twice daily after 2 to 4 weeks. Six of the nine patients were diagnosed with grade IV glioblastoma multiforme. Since diagnosis, all but one patients are still alive (mean survival time 22.3 months, range=7-47 months); one of them for almost four years, another for almost three years with no signs of progression or new lesions. The mean duration of treatment with CBD for these six patients was actually 17.5 months (range=7-28 months). Patient's quality of life and survival of this cohort is encouraging and seems to exceed the usual survival in comparable populations.

Dose of CBD and treatment schedule in our patients differed from the low-dose (average 2×10 mg/day, up to 60 mg/day), three days on/three days off schedule applied to cancer patients, as previously reported (16). Up to now, no systematic dose-effect study has been published; the optimal dose and treatment schedule for CBD remains to be elucidated. It may be dependent on the indication. Effects of CBD are very complex (13). Among other targets, CBD influences the levels of endocannabinoids such as of anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Doses of 800 mg CBD/day have been found to increase the AEA levels to approximately 1 pmol/ml after 28 days (17); steady state blood levels around 838-852 ng CBD/ml have been observed after a dose of 800 mg daily (18). Lower doses of CBD result in much lower blood levels (C<sub>max</sub> of 257-314 ng/ml after 250 mg, and ~1 ng CBD/ml after 5.4 mg CBD respectively; 18, 19). This is in the order where cannabinoids have been found, *in vitro*, to stimulate the growth of various cancer cells (20). Concerning AEA, an anticarcinogenic, concentration-dependent effect on glioblastoma cells was observed in micromolar concentrations (1 to 10 μM) *in vitro*, and in picomolar doses per kg *in vivo* (21); AEA inhibited proliferation as well as cellular migration, and induced apoptosis in micromolar concentrations.

In animal cancer models, doses (administered mainly by intraperitoneal route) differed widely between 1 and 100 mg CBD/kg. To note, in animals, dosing is most often "rhythmic", with a 5-day on and a 2-day off treatment. At present, its synergistic effects with concomitant chemotherapeutic agents remains elusive. It was therefore prudent in our eyes to administer CBD doses known to be effective for other indications.

Many biological processes are subject of circadian (24 h) and/or circaseptan (weekly) rhythmicity, dosing at the most appropriate (but unknown) time of the day and/or rhythmic

dosing with days off may produce different outcomes than the “canonical” continuous dosing. In healthy adults, endocannabinoid blood levels demonstrate marked circadian rhythmicity with more than three times higher 2-AG levels around 12.00 to 13.00 in the afternoon than at 03.30 to 04.30 in the morning (22).

In diseased subjects, the endocannabinoid system is dysregulated. Although results were somewhat conflicting, AEA levels seemed to be lower and 2-AG levels were upregulated in glioblastomas (20). Glioma invasiveness has been linked to the tumour suppressor p38 MAPK; the anti-invasive effect of CBD interferes with this pathway (23). Increased expression and activity of p38 MAPK correlates with poor prognosis in glioblastoma multiforme. Intriguingly, the levels of phosphorylated p38 MAPK are significantly reduced in clock-deficient glioma cells, indicating that the circadian clock plays an important role in activation of this pathway (24).

In summary, preliminary observations suggest a potential role of CBD in the treatment of glioma whereby the optimal dose and dosing schedule remains to be elucidated.

### Conflicts of Interest

There are no conflicts of interest to disclose regarding this study. The Authors received no financial support for this case series.

### Authors' Contributions

RL, MK, MS performed the clinical patient work. GN consulted physicians on cannabinoids and wrote the manuscript.

### References

- de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St Germaine-Smith C, Day L, Lam D and Jette N: The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. *Neuro-Oncology* 17: 776-783, 2015. PMID: 25313193. DOI: 10.1093/neuonc/nou283
- Bundesministerium f. Gesundheit (Austrian Ministry of Health) 2015 Trends der Entwicklung von Krebserkrankungen in Österreich. Available at: [www.bmg.gv.at](http://www.bmg.gv.at) (last accessed August 2019).
- Cancer Research UK: Brain, other CNS and intracranial tumours incidence statistics. Available at: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/brain-other-cns-and-intracranial-tumours/incidence> (last accessed August 2019).
- Czapski B, Baluszek S, Herold-Mende C and Kaminska B: Clinical and immunological correlates of long-term survival in glioblastoma. *Contemp Oncol (Pozn)* 22(1A): 81-85, 2018. PMID: 29628799. DOI: 10.5114/wo.2018.73893
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *New Engl J Med* 352: 987-996, 2005. PMID: 15758009. DOI: 10.1056/NEJMoa043330
- Stupp R and Roila F: ESMO Guidelines Working Group Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 20: 126-128, 2009. PMID: 19454432. DOI: 10.1093/annonc/mdp151
- Karotki KJLC, Azam A and Hamerlik P: The heterogeneity and therapeutic resistance of glioblastoma. *Med Res Arch* 3: 1-21, 2015. Available at: <https://journals.ke-i.org/index.php/mra/article/view/229> (last accessed September 2019).
- Likar R and Nahler G: The use of cannabis in supportive care and treatment of brain tumor. *Neuro-Oncology Practice* 4: 151-160, 2017. DOI: 10.1093/nop/npw027
- Dall’Stella PB, Docema MFL, Maldaun MVC, Feher O and Lancellotti CLP: Case report: Clinical outcome and image response of two patients with secondary high-grade glioma treated with chemoradiation, PCV, and cannabidiol. *Front Oncol* 8: 643, 2019. DOI: 10.3389/fonc.2018.00643
- Foroughi M, Hendson G, Sargent MA and Steinbok P: Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas—possible role of Cannabis inhalation. *Childs Nerv Syst* 27: 671-679, 2011. PMID: 21336992. DOI: 10.1007/s00381-011-1410-4
- Kander J: The Comprehensive Report on the Cannabis Extract Movement and the Use of Cannabis Extracts to Treat Diseases. 8th ed. February 2016, Nicholas Davey, (ed.). Available at <https://www.amazon.com/Comprehensive-Cannabis-Movement-Extracts-Diseases-ebook/dp/B00FZVRYL2> (last accessed August 2019)
- Nottingham University’s Children’s Brain Tumour Centre: New British study on CBD and pediatric tumors. Available at: <https://cashcbdoil.com/2019/04/21/new-british-study-on-cbd-and-pediatric-tumors/> (last accessed August 2019)
- Nahler G, Jones T and Russo EB: Cannabidiol and contributions of major hemp phytochemicals to the “Entourage Effect”; possible mechanisms. *J Altern Complement Integr Med* 5: 070, 2019. DOI: 10.24966/ACIM-7562/100066
- Twelves C, Short S and Wright S: A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM). *J Clin Oncol* 35: 2046-2046, 2017. DOI: 10.1200/JCO.2017.35.15\_suppl.2046
- Guzman M, Duarte MJ, Blazquez C, Ravina J, Rosa MC, Galve-Roperh I, Sanchez C, Velasco G and Gonzalez-Feria L: A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. *Brit J Cancer* 95: 197-203. PMID: 16804518. DOI: 10.1038/sj.bjc.6603236
- Kenyon J, Liu W and Dalglish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38: 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924
- Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M and Koethe D: Cannabidiol enhances anandamide signalling and alleviates psychotic

- symptoms of schizophrenia. *Transl Psychiatry* 2: e94, 2012. PMID: 22832859. DOI: 10.1038/tp.2012.15
- 18 Morrison G, Crockett J, Blakey G and Sommerville K: A phase I, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. *Clin Pharmacol Drug Dev*, 2019. PMID: 30791225. DOI: 10.1002/cpdd.665
- 19 Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM and Stadelmann AM: Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of delta-9-tetrahydrocannabinol (THC) after oral application of THC versus standardized cannabis extract. *Ther Drug Monit* 27: 799-810, 2005. PMID: 16306858. DOI: 10.1097/01.ftd.0000177223.19294.5c
- 20 Fraguas-Sanchez AI, Martin-Sabroso C and Torres-Suarez AI: Insights into the effects of the endocannabinoid system in cancer: a review. *Br J Pharmacol* 175: 2566-2580, 2018. PMID: 29663308. DOI: 10.1111/bph.14331
- 21 Ma C, Wu TT, Jiang PC, Li ZQ, Chen XJ, Fu K, Wang W and Gong R: Anticarcinogenic activity of anandamide on human glioma *in vitro* and *in vivo*. *Mol Med Rep* 13: 1558-1562, 2016. PMID: 26707955. DOI: 10.3892/mmr.2015.4721
- 22 Hanlon EC, Tasali E, Leproult R, Stuhr KL, Doncheck E, de Witt H, Hillard CJ and Van Cauter E: Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerol. *J Clin Endocrinol Metab* 100(1): 220-226, 2015. PMID: 25368979. DOI: 10.1210/jc.2014-3455
- 23 Ramer R, Merkord J, Helga Rohde and Hinz B: Cannabidiol inhibits cancer cell invasion *via* upregulation of tissue inhibitor of matrix metalloproteinases-1. *Biochem Pharmacol* 79: 955-966, 2010. PMID: 19914218. DOI: 10.1016/j.bcp.2009.11.007
- 24 Goldsmith CS, Kim SM, Karunarathna N, Neuendorff N, Toussaint LG, Earnest DJ and Bell-Pedersen D: Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness. *BMC Cancer* 18(1): 43, 2018. PMID: 29316898. DOI: 10.1186/s12885-017-3896-y

*Received September 5, 2019*

*Revised September 17, 2019*

*Accepted September 18, 2019*

## Instructions for Authors 2019

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dalglish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at [http://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index2.html](http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html). Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).



**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html> In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email ([iiar@iiar-anticancer.org](mailto:iiar@iiar-anticancer.org)) within two days.

### **Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
- The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
- they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.
- (Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2019** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.